Hsiang-Ju Pan1, Hong-Tai Chang2, Chien-Hung Lee3. 1. Department of Family Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Electronic address: philia81301@gmail.com. 2. Department of General Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. 3. School of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan.
Abstract
BACKGROUND/ PURPOSE: For estrogen-receptor positive breast cancer cases, tamoxifen has been the most important adjuvant hormonal therapy for the purpose of reducing recurrence rates and prolonging disease free survival. However, several side effects have been noticed, and fatty liver is one of the most common side effects among them. Since fatty liver is a common problem in the general population, we wanted to examine the effects of tamoxifen under pre-existing fatty liver conditions and evaluate the prevalence of tamoxifen-related impaired liver function. METHODS: We recruited breast cancer cases at ages 20-70 years and divided them into tamoxifen or control groups. Personal information was collected, and fasting blood tests and abdominal ultrasound were performed. The changes of fatty liver degree between the initial and follow-up ultrasound were divided into five categories. RESULTS: Of the 406 enrolled participants, 266 were in the tamoxifen group and 140 were in the control group. The tamoxifen group had a higher risk of newly developed fatty liver [hazard ratio (HR) = 3.69; 95% confidence interval (CI) 1.67-8.13), lower rate of improved fatty liver (HR = 0.33; 95% CI 0.15-0.75), and higher rate of worsened fatty liver (HR = 2.11; 95% CI 1.02-4.35). CONCLUSION: The current study suggests that tamoxifen treatment is associated with the risk of fatty liver either by increasing the risk of newly developed fatty liver conditions or worsening previous fatty liver conditions, and even retarding fatty liver improvement.
BACKGROUND/ PURPOSE: For estrogen-receptor positive breast cancer cases, tamoxifen has been the most important adjuvant hormonal therapy for the purpose of reducing recurrence rates and prolonging disease free survival. However, several side effects have been noticed, and fatty liver is one of the most common side effects among them. Since fatty liver is a common problem in the general population, we wanted to examine the effects of tamoxifen under pre-existing fatty liver conditions and evaluate the prevalence of tamoxifen-related impaired liver function. METHODS: We recruited breast cancer cases at ages 20-70 years and divided them into tamoxifen or control groups. Personal information was collected, and fasting blood tests and abdominal ultrasound were performed. The changes of fatty liver degree between the initial and follow-up ultrasound were divided into five categories. RESULTS: Of the 406 enrolled participants, 266 were in the tamoxifen group and 140 were in the control group. The tamoxifen group had a higher risk of newly developed fatty liver [hazard ratio (HR) = 3.69; 95% confidence interval (CI) 1.67-8.13), lower rate of improved fatty liver (HR = 0.33; 95% CI 0.15-0.75), and higher rate of worsened fatty liver (HR = 2.11; 95% CI 1.02-4.35). CONCLUSION: The current study suggests that tamoxifen treatment is associated with the risk of fatty liver either by increasing the risk of newly developed fatty liver conditions or worsening previous fatty liver conditions, and even retarding fatty liver improvement.
Authors: Hee Yeon Noh; Su Joa Ahn; Sang Yu Nam; Young Rock Jang; Yong Soon Chun; Heung Kyu Park; Seung Joon Choi; Hye Young Choi; Jeong Ho Kim Journal: J Med Ultrasound Date: 2022-06-08
Authors: Tian Du; Matthew J Sikora; Kevin M Levine; Nilgun Tasdemir; Rebecca B Riggins; Stacy G Wendell; Bennett Van Houten; Steffi Oesterreich Journal: Breast Cancer Res Date: 2018-09-04 Impact factor: 6.466
Authors: Jeong-Ju Yoo; Yong Seok Lim; Min Sung Kim; Bora Lee; Bo-Yeon Kim; Zisun Kim; Ji Eun Lee; Min Hee Lee; Sang Gyune Kim; Young Seok Kim Journal: PLoS One Date: 2020-07-30 Impact factor: 3.240